Skip to main content
Premium Trial:

Request an Annual Quote

ACLARA and Caliper Settle Suits and Cross-License Technology

NEW YORK, Jan 8 – Aclara Biosciences and Caliper technologies have reached a settlement agreement on three lawsuits, and have agreed to cross-license their microfluidics technologies, Aclara announced late Sunday.

Under the settlement, Aclara will license Caliper’s plastic chip technology, Caliper will license Aclara’s glass chip technology, and Aclara will issue 900,000 shares of its common stock to Caliper. The companies have also set up a private dispute resolution process to handle any future conflicts.

If Caliper's shares of Aclara’s stock do not reach a total value of $32 million, or $36.11 per share in 18 months, Aclara will also make a cash payment to Caliper to make up for the difference between $32 million and the stock value. On Monday morning, Aclara’s stock was trading at 14 ½, up 2 7/8 since Friday’s close.

This settlement comes after a long, complex battle in which a jury granted Caliper $52 million in damages against Aclara for misappropriating its trade secrets. A judge reduced these damages by $17 million. Meanwhile, Caliper had sued Aclara for infringing its lab-on-chip technology, and Aclara had sued Caliper for infringing on its microfluidics methods. These suits are dismissed as a result of the settlement.

" We are pleased to have a comprehensive resolution to this litigation, and believe that this settlement is positive for Aclara, our partners and our shareholders,” Aclara CEO Joseph Limber said in a statement. “[T]his settlement will allow Aclara's management and scientific resources to focus on product development and commercialization, which is how we intend to deliver value to our shareholders."

Caliper could not immediately be reached for comment.
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.